Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · IEX Real-Time Price · USD
8.00
-0.05 (-0.62%)
At close: Apr 19, 2024, 3:59 PM
8.13
+0.13 (1.63%)
After-hours: Apr 19, 2024, 4:12 PM EDT

Company Description

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.

The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.

The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.

Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Telomir Pharmaceuticals, Inc.
Country United States
Founded 2021
IPO Date Feb 9, 2024
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Dr. Christopher Chapman, Jr.

Contact Details

Address:
900 West Platt Street, Suite 200
Tampa, Florida 33606
United States
Phone (813) 864-2562
Website telomirpharma.com

Stock Details

Ticker Symbol TELO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $7.00
CIK Code 0001971532
Employer ID 87-2606031
SIC Code 2834

Key Executives

Name Position
Dr. Christopher C. Chapman Jr., M.D. Co-Founder, Chairman and Chief Executive Officer
Nathen Fuentes CPA Chief Financial Officer, Treasurer, and Secretary
Christos Nicholoudis Esq. General Counsel and Director

Latest SEC Filings

Date Type Title
Apr 15, 2024 8-K Current Report
Apr 12, 2024 8-K Current Report
Mar 29, 2024 10-K Annual Report
Feb 13, 2024 8-K Current Report
Feb 12, 2024 424B4 Prospectus
Feb 12, 2024 424B1 Filing
Feb 8, 2024 EFFECT Notice of Effectiveness
Feb 8, 2024 CERT Certification by an exchange approving securities for listing
Feb 6, 2024 8-A12B Registration of securities
Jan 3, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933